| Targeting tumor-associated carbonic anhydrase IX in cancer therapy A Thiry, JM Dogne, B Masereel, CT Supuran Trends in pharmacological sciences 27 (11), 566-573, 2006 | 481 | 2006 |
| Impact of dabigatran on a large panel of routine or specific coagulation assays J Douxfils, F Mullier, S Robert, C Chatelain, B Chatelain, JM Dogné Thrombosis and haemostasis 107 (05), 985-997, 2012 | 465 | 2012 |
| Adverse cardiovascular effects of the coxibs JM Dogné, CT Supuran, D Pratico Journal of medicinal chemistry 48 (7), 2251-2257, 2005 | 433 | 2005 |
| Standardization of pre-analytical variables in plasma microparticle determination: results of the International Society on Thrombosis and Haemostasis SSC Collaborative workshop R Lacroix, C Judicone, M Mooberry, M Boucekine, NS Key, ... Journal of Thrombosis and Haemostasis 11 (6), 1190-1193, 2013 | 382 | 2013 |
| Laboratory testing in patients treated with direct oral anticoagulants: a practical guide for clinicians J Douxfils, W Ageno, CM Samama, S Lessire, H Ten Cate, P Verhamme, ... Journal of Thrombosis and Haemostasis 16 (2), 209-219, 2018 | 375 | 2018 |
| Impact of apixaban on routine and specific coagulation assays: a practical laboratory guide J Douxfils, C Chatelain, B Chatelain, JM Dogné, F Mullier Thrombosis and Haemostasis 110 (08), 283-294, 2013 | 316* | 2013 |
| Assessment of the impact of rivaroxaban on coagulation assays: laboratory recommendations for the monitoring of rivaroxaban and review of the literature J Douxfils, F Mullier, C Loosen, C Chatelain, B Chatelain, JM Dogné Thrombosis research 130 (6), 956-966, 2012 | 288 | 2012 |
| Carbonic anhydrase inhibitors as anticonvulsant agents A Thiry, JM Dogne, CT Supuran, B Masereel Current topics in medicinal chemistry 7 (9), 855-864, 2007 | 240 | 2007 |
| Specific inhibition of carbonic anhydrase IX activity enhances the in vivo therapeutic effect of tumor irradiation L Dubois, S Peeters, NG Lieuwes, N Geusens, A Thiry, S Wigfield, F Carta, ... Radiotherapy and Oncology 99 (3), 424-431, 2011 | 212 | 2011 |
| Association between BCR-ABL tyrosine kinase inhibitors for chronic myeloid leukemia and cardiovascular events, major molecular response, and overall survival: a systematic … J Douxfils, H Haguet, F Mullier, C Chatelain, C Graux, JM Dogne JAMA oncology 2 (5), 625-632, 2016 | 198 | 2016 |
| Comparison of calibrated chromogenic anti-Xa assay and PT tests with LC-MS/MS for the therapeutic monitoring of patients treated with rivaroxaban J Douxfils, A Tamigniau, B Chatelain, C Chatelain, P Wallemacq, ... Thrombosis and haemostasis 110 (10), 723-731, 2013 | 186 | 2013 |
| Coxibs and cardiovascular side-effects: from light to shadow JM Dogné, J Hanson, C Supuran, D Pratico Current pharmaceutical design 12 (8), 971-975, 2006 | 184 | 2006 |
| Solid lipid microparticles as a sustained release system for pulmonary drug delivery S Jaspart, P Bertholet, G Piel, JM Dogné, L Delattre, B Evrard European journal of pharmaceutics and biopharmaceutics 65 (1), 47-56, 2007 | 180 | 2007 |
| Antibody titres decline 3-month post-vaccination with BNT162b2 J Favresse, JL Bayart, F Mullier, M Elsen, C Eucher, S Van Eeckhoudt, ... Emerging microbes & infections 10 (1), 1495-1498, 2021 | 162 | 2021 |
| Anticonvulsant sulfonamides/sulfamates/sulfamides with carbonic anhydrase inhibitory activity: drug design and mechanism of action A Thiry, JM Dogne, CT Supuran, B Masereel Current pharmaceutical design 14 (7), 661-671, 2008 | 150 | 2008 |
| Comparison of calibrated dilute thrombin time and aPTT tests with LC-MS/MS for the therapeutic monitoring of patients treated with dabigatran etexilate J Douxfils, JM Dogné, F Mullier, B Chatelain, Y Rönquist-Nii, ... Thrombosis and haemostasis 110 (09), 543-549, 2013 | 143 | 2013 |
| Ir-CPI, a coagulation contact phase inhibitor from the tick Ixodes ricinus, inhibits thrombus formation without impairing hemostasis Y Decrem, G Rath, V Blasioli, P Cauchie, S Robert, J Beaufays, JM Frère, ... Journal of Experimental Medicine 206 (11), 2381-2395, 2009 | 138 | 2009 |
| Thromboxane, prostacyclin and isoprostanes: therapeutic targets in atherogenesis JM Dogné, J Hanson, D Pratico Trends in pharmacological sciences 26 (12), 639-644, 2005 | 137 | 2005 |
| Pathophysiology, diagnosis, and treatment of paroxysmal nocturnal hemoglobinuria: a review B Devalet, F Mullier, B Chatelain, JM Dogné, C Chatelain European journal of haematology 95 (3), 190-198, 2015 | 133 | 2015 |
| Prostanoids as pharmacological targets in COPD and asthma S Rolin, B Masereel, JM Dogné European journal of pharmacology 533 (1-3), 89-100, 2006 | 126 | 2006 |
François MullierUniversité catholique de Louvain, CHU UCL NamurVerified email at uclouvain.be
